ISO 10993-7:2026 introduces significant updates to the evaluation of ethylene oxide (EO) and ethylene chlorohydrin (ECH) residuals in EO-sterilized medical devices. The revised standard places greater emphasis on patient-specific exposure assumptions, cumulative exposure assessment, risk-based justification, and clinically relevant extraction strategies. Manufacturers must demonstrate not only compliance with applicable residual limits but also that testing, exposure calculations, product categorization, and release strategies accurately reflect intended clinical use. This whitepaper highlights the key changes introduced in the 2026 edition, including updated approaches to patient population considerations, cumulative exposure evaluation, extraction methodology, product release pathways, and assessment of existing products. Download today to identify practical considerations for manufacturers preparing to implement and document compliance under the revised framework.
